FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and high visual acuity.
Update on Geographic Atrophy in Age-Related Macular Degeneration.
Ranibizumab in the treatment of choroidal neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome.
Management of Retinal Vein Occlusion — Consensus Document.
Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Postsurgical cystoid macular edema
Retinal vein occlusions.
As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. (FALTA)
A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice.
Optical Coherence Tomography Assessment of Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy.
GAIN. Characterization of geographic atrophy progression in patients with age-related macular degeneration: evolution and risk factors associated with geographic atrophy progression
Oral Omega 3 Drusen: A phase II randomized, double-mask study to establish the safety and efficacy of High-Dose Oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration
The Brighter Study: a 24-month, phase IIIB, open-label, randomized, active controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)
The Crystal Study: a 24-month, phase IIIB, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)